Our findings provide the exciting opportunity that specifically targeting CAFs with STING agonists can promote an antitumor phenotype in TANs in addition to suppressing the prometastatic influence of CAFs on tumor cells in PDAC. The gene discussed is STING1; the disease is neoplasm.